

# DesirÃ©e Hao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8007714/publications.pdf>

Version: 2024-02-01

62  
papers

1,313  
citations

304368

22  
h-index

360668

35  
g-index

63  
all docs

63  
docs citations

63  
times ranked

2370  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort. <i>Current Oncology</i> , 2022, 29, 1967-1982.	0.9	1
2	TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report. <i>Current Oncology</i> , 2022, 29, 3933-3939.	0.9	8
3	Piloting virtual mentorship: Evaluating acceptability and influence on wellness and professional identity in medical oncology (MO).. <i>Journal of Clinical Oncology</i> , 2022, 40, 11022-11022.	0.8	0
4	Canadian medical oncology workforce and cancer incidence trends: Supply and proxy demand analyses from 1994 to 2020.. <i>Journal of Clinical Oncology</i> , 2022, 40, e13526-e13526.	0.8	0
5	Patient and caregiver-reported acceptability of an automatic phone call offering supportive and palliative care referral for advanced non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, e24097-e24097.	0.8	0
6	Assessment Of Tumour Infiltrating Lymphocytes And Pd-l1 Expression In Adenoid Cystic Carcinoma Of The Salivary Gland. <i>Clinical and Investigative Medicine</i> , 2021, 44, E38-41.	0.3	11
7	Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100157.	0.6	7
8	Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy. <i>Cancers</i> , 2020, 12, 1926.	1.7	7
9	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. <i>Future Oncology</i> , 2020, 16, 2799-2808.	1.1	50
10	The Gut Microbiota: A Potential Gateway to Improved Health Outcomes in Breast Cancer Treatment and Survivorship. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9239.	1.8	29
11	Intraparenchymal epithelioid malignant mesothelioma: A case report. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2020, 4, 61-63.	0.2	0
12	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. <i>Lung Cancer</i> , 2020, 143, 1-11.	0.9	19
13	Demonstrating the value of liquid biopsy for lung cancer in a public health care system.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3546-3546.	0.8	3
14	Abstract A26: Defining VALUE: Routine liquid biopsy in NSCLC diagnosis—a Canadian trial in progress. , 2020, , .		0
15	Abstract PO-029: Operationalizing a prioritized COVID-19 testing strategy at a Canadian tertiary care cancer center. , 2020, , .		0
16	Sequential afatinib and osimertinib in patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. <i>Future Oncology</i> , 2019, 15, 2905-2914.	1.1	71
17	MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study. <i>Diagnostic Pathology</i> , 2019, 14, 78.	0.9	7
18	Impact of Asian ethnicity on outcome in metastatic <i>EGFR</i> mutant non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 343-352.	0.7	11

#	ARTICLE	IF	CITATIONS
19	Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. <i>Lung Cancer</i> , 2018, 120, 142-148.	0.9	37
20	Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. <i>Future Oncology</i> , 2018, 14, 2861-2874.	1.1	90
21	Abstract A89: Gender and racial disparities in non-small cell lung cancer: A systematic review. , 2018, , .		0
22	A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group. <i>Lung Cancer</i> , 2017, 104, 65-69.	0.9	19
23	MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226. <i>Journal of Thoracic Oncology</i> , 2017, 12, S392-S393.	0.5	12
24	Paraneoplastic neuropsychiatric syndrome presenting as delirium. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, 218-220.	0.8	4
25	Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation. <i>Cmaj</i> , 2017, 189, E1030-E1040.	0.9	40
26	Distress levels in patients with oropharyngeal vs. non-oropharyngeal squamous cell carcinomas of the head and neck over 1 year after diagnosis: a retrospective cohort study. <i>Supportive Care in Cancer</i> , 2017, 25, 3225-3233.	1.0	9
27	Immune related adverse events (irAE) with platinum chemotherapy (CT) with durvalumab (D) ± tremelimumab (T): CCTG IND226.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3058-3058.	0.8	2
28	Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC. <i>Oncotarget</i> , 2017, 8, 38326-38336.	0.8	22
29	ATM, THMS, and RRM1 protein expression in nasopharyngeal carcinomas treated with curative intent. <i>Head and Neck</i> , 2016, 38, E384-91.	0.9	8
30	Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 810-815.	0.8	79
31	Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment. <i>Metabolomics</i> , 2016, 12, 58.	1.4	47
32	Secondary Neuroendocrine Carcinoma Following High-Dose Radiotherapy for Head and Neck Cancer: Report of Two Cases. <i>Cureus</i> , 2016, 8, e847.	0.2	4
33	Trends in the incidence of human papillomavirus-related noncervical and cervical cancers in Alberta, Canada: a population-based study. <i>CMAJ Open</i> , 2014, 2, E127-E132.	1.1	27
34	Dose Delivery Analysis of Weekly Versus 3-Weekly Cisplatin Concurrent With Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 63-69.	0.6	21
35	Pan-Canadian rash trial with EGFR inhibitors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8013-8013.	0.8	3
36	Evaluation of E-cadherin, β2-catenin and vimentin protein expression using quantitative immunohistochemistry in nasopharyngeal carcinoma patients. <i>Clinical and Investigative Medicine</i> , 2014, 37, 320.	0.3	12

#	ARTICLE	IF	CITATIONS
37	Assessment of ERCC1 and XPF Protein Expression Using Quantitative Immunohistochemistry in Nasopharyngeal Carcinoma Patients Undergoing Curative Intent Treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1340-1345.	0.4	11
38	Abstract 3545: ATM, TS and RRM1 protein expression in nasopharyngeal carcinomas (NPC) treated with curative intent.. , 2013, , .		0
39	An analysis of the temporal, age, and gender trends in human papillomavirus virus (HPV)-related versus non-HPV-related head and neck cancers (HNC) in Alberta, Canada.. <i>Journal of Clinical Oncology</i> , 2013, 31, e12505-e12505.	0.8	0
40	Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 579-586.	0.5	74
41	Comparing ERCC1 protein expression, mRNA levels, and genotype in squamous cell carcinomas of the head and neck treated with concurrent chemoradiation stratified by HPV status. <i>Head and Neck</i> , 2012, 34, 785-791.	0.9	17
42	A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 815-824.	1.1	6
43	The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 563-571.	1.1	16
44	A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3013-3013.	0.8	5
45	CXCR4 Overexpression Is Associated with Poor Outcome in Females Diagnosed with Stage IV Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1169-1178.	0.5	60
46	Prognostic significance of p16 in locally advanced squamous cell carcinoma of the head and neck treated with concurrent cisplatin and radiotherapy. <i>Head and Neck</i> , 2011, 33, 251-256.	0.9	35
47	High Stromal Carbonic Anhydrase IX Expression Is Associated With Decreased Survival in p16-Negative Head-and-Neck Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 249-257.	0.4	37
48	Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone. <i>Radiotherapy and Oncology</i> , 2010, 97, 352-359.	0.3	33
49	Abstract 1742: Evaluating the prognostic value of EGFR by p16/HPV status in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiation. , 2010, , .		0
50	Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 65, 167-175.	1.1	2
51	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 911-919.	1.1	37
52	P2-241: A retrospective study of the role of chemotherapy in non-small cell lung cancer (nsc) patients with brain metastases treated in Alberta, Canada from 2000-2004. <i>Journal of Thoracic Oncology</i> , 2007, 2, S668-S669.	0.5	0
53	B1-02: A Phase 1-2 study of the anti-sense oligonucleotide OGX-011 in combination with a platinum/gemcitabine regimen as first-line therapy for advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, S333.	0.5	0
54	P3-125: Similar characteristics of responders treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) Gefitinib and Erlotinib for advanced non small cell lung cancer (NSCLC) in a single Canadian institution.. <i>Journal of Thoracic Oncology</i> , 2007, 2, S732.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Platinum-Based Concurrent Chemoradiotherapy for Tumors of the Head and Neck and the Esophagus. <i>Seminars in Radiation Oncology</i> , 2006, 16, 10-19.	1.0	23
56	Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity. <i>Head and Neck</i> , 2006, 28, 189-196.	0.9	24
57	Clinical Cancer Advances 2005: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2006, 24, 190-205.	0.8	108
58	Phase I, Pharmacokinetic, and Pharmacodynamic Study of Intravenously Administered Ad5CMV-p53, an Adenoviral Vector Containing the Wild-Type p53 Gene, in Patients With Advanced Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2052-2058.	0.8	49
59	Acceleration of Telomere Loss by Chemotherapy Is Greater in Older Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 6345-6350.	3.2	48
60	Inhibiting Signal Transduction: Recent Advances in the Development of Receptor Tyrosine Kinase and Ras Inhibitors. <i>Cancer Investigation</i> , 2002, 20, 387-404.	0.6	31
61	Promising Developments in Targeted Therapies for non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 111-123.	1.1	3
62	Preclinical antitumor activity and pharmacokinetics of methyl-2-benzimidazolecarbamate (FB642). <i>Investigational New Drugs</i> , 2002, 20, 261-270.	1.2	32